Alizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.
Alizapride is a dopamine antagonist.
Mode of Action:
The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)ãthis action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics.
Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M: Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol. 1988;22(4):316-20. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs